Petrie M. Rainey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Petrie M. Rainey has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Laurie Andrews
2 shared publicationsPeter Jatlow
From Yale University School of Medicine, New Haven, Conn
2 shared publicationsSusan M. Mitchell
2 shared publicationsBarbara Lane
Glaxo Wellcome, Research Triangle Park, NC
1 shared publicationChristina Charles
1 shared publication- Elinore F. McCance-Katz1 shared publication
Latest Publications
- Open Access
- 23 July 2013
- Published by SAGE Publications in Journal of the International Association of Providers of AIDS Care (JIAPAC)
- Vol. 12 (6) , 375-377
Interactions between Alcohol and the HIV Entry Inhibitor Maraviroc
Background: Alcohol use is common among people with HIV, and beliefs about alcohol interactions with medications predict decreased medication adherence, risking drug-resistant mutations. Maraviroc is an HIV entry inhibitor approved for treatment of both drug-sensitive and drug-resistant HIV strains. The present study evaluated the effects of alcohol on maraviroc pharmacokinetics and the effects of maraviroc on alcohol pharmacokinetics. Methods: Ten healthy adults completed alcohol (1 g/kg) and placebo alcohol pharmacokinetics sessions before and after 7 days of maraviroc administration. Results: Alcohol concentrations increased 12% following maraviroc. Maraviroc pharmacokinetics were unaffected by alcohol. Conclusions: Maraviroc treatment should not be interrupted if alcohol is consumed.
- 23 July 2013
- Published by SAGE Publications in Journal of the International Association of Providers of AIDS Care (JIAPAC)
- Vol. 12 (6) , 375-377
Open AccessInteractions between Alcohol and the HIV Entry Inhibitor Maraviroc
Background: Alcohol use is common among people with HIV, and beliefs about alcohol interactions with medications predict decreased medication adherence, risking drug-resistant mutations. Maraviroc is an HIV entry inhibitor approved for treatment of both drug-sensitive and drug-resistant HIV strains. The present study evaluated the effects of alcohol on maraviroc pharmacokinetics and the effects of maraviroc on alcohol pharmacokinetics. Methods: Ten healthy adults completed alcohol (1 g/kg) and placebo alcohol pharmacokinetics sessions before and after 7 days of maraviroc administration. Results: Alcohol concentrations increased 12% following maraviroc. Maraviroc pharmacokinetics were unaffected by alcohol. Conclusions: Maraviroc treatment should not be interrupted if alcohol is consumed.
- 1 December 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (12) , 2184-2187
Automatic Reporting of Estimated Glomerular Filtration Rate—Jumping the Gun?
- 1 December 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (12) , 2184-2187
Automatic Reporting of Estimated Glomerular Filtration Rate—Jumping the Gun?
- 1 February 2002
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (1) , 26-31
HIV Drug Interactions: The Good, the Bad, and the Other
Highly active antiretroviral therapy, involving treatment with three or four antiretroviral agents, has greatly improved the effectiveness of therapy for human immunodeficiency virus (HIV) infection. It has also extended the number of possible drug interactions that may occur in treated patients. There are 105 possible two-drug interactions among the 15 currently approved antiretroviral agents. Well-characterized interactions involving inhibition of drug metabolism have been exploited to reduce dose size or frequency and to simplify treatment regimens. Many additional interactions are possible with other drugs used to treat or prevent complications of HIV infection. Interactions with methadone and other opiate abuse therapies are also of concern. The usefulness of therapeutic drug monitoring for antiretroviral drugs remains controversial. However, drug measurements before introduction of an interacting drug can establish patient-specific targets that can guide subsequent dosing adjustment.
- 1 February 2002
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (1) , 26-31
HIV Drug Interactions: The Good, the Bad, and the Other
Highly active antiretroviral therapy, involving treatment with three or four antiretroviral agents, has greatly improved the effectiveness of therapy for human immunodeficiency virus (HIV) infection. It has also extended the number of possible drug interactions that may occur in treated patients. There are 105 possible two-drug interactions among the 15 currently approved antiretroviral agents. Well-characterized interactions involving inhibition of drug metabolism have been exploited to reduce dose size or frequency and to simplify treatment regimens. Many additional interactions are possible with other drugs used to treat or prevent complications of HIV infection. Interactions with methadone and other opiate abuse therapies are also of concern. The usefulness of therapeutic drug monitoring for antiretroviral drugs remains controversial. However, drug measurements before introduction of an interacting drug can establish patient-specific targets that can guide subsequent dosing adjustment.
- 1 January 2002
- Published by Wiley in The American Journal on Addictions
- Vol. 11 (1) , 66-74
The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects
Methadone pharmacokinetics were determined in an open‐label, within subject study in 16 methadone‐maintained, non‐HIV‐infected subjects prior to and following administration of one lamivudine 150‐mg/zidovudine 300‐mgcombi‐nation tablet to determine whether this antiretroviral therapy alters methadone serum concentrations. No significant differences in the mean are aunder the serum concentration‐time curve (AUC0‐24h; 8753 ± 4280 vs. 8641 ± 4431 μg‐h/L), oralclearance(CL/F;9.9± 4.9vs.10.3 ± 5.5 L/h), oral volume of distribution (Vd/F; 647 ± 465 vs. 481 ± 305 L), maximum serum concentration (Cmax; 514 ± 223 vs. 5510 ± 237 μg/L), or terminal elimination half‐life (tl/2; 55.3 ± 61.0 vs. 35.0 ± 17.5 h) were detected. These results suggest that methadone dose change is not likely to be necessary for patients treated with lamivudine/zidovudine combination pharmacotherapy.
- 1 January 2002
- Published by Wiley in The American Journal on Addictions
- Vol. 11 (1) , 66-74
The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects
Methadone pharmacokinetics were determined in an open‐label, within subject study in 16 methadone‐maintained, non‐HIV‐infected subjects prior to and following administration of one lamivudine 150‐mg/zidovudine 300‐mgcombi‐nation tablet to determine whether this antiretroviral therapy alters methadone serum concentrations. No significant differences in the mean are aunder the serum concentration‐time curve (AUC0‐24h; 8753 ± 4280 vs. 8641 ± 4431 μg‐h/L), oralclearance(CL/F;9.9± 4.9vs.10.3 ± 5.5 L/h), oral volume of distribution (Vd/F; 647 ± 465 vs. 481 ± 305 L), maximum serum concentration (Cmax; 514 ± 223 vs. 5510 ± 237 μg/L), or terminal elimination half‐life (tl/2; 55.3 ± 61.0 vs. 35.0 ± 17.5 h) were detected. These results suggest that methadone dose change is not likely to be necessary for patients treated with lamivudine/zidovudine combination pharmacotherapy.
- 1 July 2000
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 24 (3) , 241-248
Interaction of Methadone with Didanosine and Stavudine
- 1 July 2000
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 24 (3) , 241-248
Interaction of Methadone with Didanosine and Stavudine